Indicated for the treatment of adult patients with Non-Small Cell Lung Cancer (NSCLC): 🔹 First-line treatment: For patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. 🔹 Second-line treatment: For patients with EGFR T790M mutation-positive NSCLC who have progressed on prior EGFR-TKI therapy. 🔹 Adjuvant therapy: After tumor resection.

Dosage and administration

Packaging: 80 mg tablets. ⚠️ ADMINISTRATION PROTOCOL: Recommended Dose: 80 mg orally once daily. Food Intake: Can be taken with or without food. Timing: Take at the same time each day. Administration: Swallow whole. If unable to swallow, the tablet may be dispersed in 50 ml of non-carbonated water (do not crush). Supply: One pack (30 tablets) provides a full 30-day supply.

Hypersensitivity to Osimertinib. Pregnancy and breastfeeding (embryo-fetal toxicity). Active Interstitial Lung Disease (ILD) or pneumonitis. QTc interval prolongation.

Common adverse reactions include: 🩸 Dermatologic: Rash, dry skin, paronychia (nail infection/inflammation), pruritus. 📉 Gastrointestinal: Diarrhea (very common), stomatitis (mouth sores). 🦠 Blood: Decreased leukocyte or platelet counts. ⚠️ Cardiac: QT prolongation (ECG monitoring is recommended).

Tagrix 80 — Osimertinib 80 mg, 30 pcs, Beacon Pharmaceuticals

100% original product

Active ingredient

Osimertinib

Manufacturer

Beacon Pharmaceuticals

Dosage 80 mg

Dosage form Tablets

Tablets per pack 30

Tagrix 80 (Osimertinib) 80 mg Tablets

Name: Tagrix 80
Brand: Beacon Pharmaceuticals
SKU: PROD-152
Price: 23293 UAH
Availability: InStock

23293₴ ~~26809₴~~ -13%

Tagrix 80 mg (Osimertinib) is a third-generation EGFR tyrosine kinase inhibitor (TKI) used for targeted lung cancer therapy.

Manufacturer: Beacon Medicare Limited. Each pack contains 30 tablets. It is designed to target specific genetic mutations, including the T790M resistance mutation, and is highly effective at crossing the blood-brain barrier to treat brain metastases.

Key Feature:

Considered the standard of care for EGFR-mutated NSCLC due to its superior efficacy and safety profile compared to earlier generation inhibitors.

Indicated for the treatment of adult patients with Non-Small Cell Lung Cancer (NSCLC):

🔹 First-line treatment: For patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
🔹 Second-line treatment: For patients with EGFR T790M mutation-positive NSCLC who have progressed on prior EGFR-TKI therapy.
🔹 Adjuvant therapy: After tumor resection.

Packaging: 80 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

Recommended Dose: 80 mg orally once daily.
Food Intake: Can be taken with or without food.
Timing: Take at the same time each day.
Administration: Swallow whole. If unable to swallow, the tablet may be dispersed in 50 ml of non-carbonated water (do not crush).
Supply: One pack (30 tablets) provides a full 30-day supply.

Hypersensitivity to Osimertinib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
Active Interstitial Lung Disease (ILD) or pneumonitis.
QTc interval prolongation.

Common adverse reactions include:

🩸 Dermatologic: Rash, dry skin, paronychia (nail infection/inflammation), pruritus.
📉 Gastrointestinal: Diarrhea (very common), stomatitis (mouth sores).
🦠 Blood: Decreased leukocyte or platelet counts.
⚠️ Cardiac: QT prolongation (ECG monitoring is recommended).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 12.04.2026